Neovasc Inc

Neovasc — Investor Presentation (May 2012)

21 slides from Neovasc's investor presentation, May 2012

  1. Slide 1: Neovasc Inc.

    Neovasc Inc. Alexei Marko, CEO Chris Clark, CFO May 2012

  2. Slide 2: Forward-Looking Statements

    Forward-Looking Statements Statements contained herein that are not based on historical or current fact, including without limitation statements containing the words “anticipates,” “believes,” “may,” “continues,” “estimates,” “expects,” and “will” and words of similar import, constitute “forward-loo

  3. Slide 3: Neovasc at-a-Glance

    Neovasc at-a-Glance • Focused on innovative products to treat heart disease & related conditions • Three key product lines with large growth potential: 1. Neovasc Reducer™ for treatment of refractory angina (CE marked) 2. Implantable biological tissue & services for transcatheter heart valves & othe

  4. Slide 4: Reducer Product

    Reducer Product Treats Refractory Angina • Inadequate blood flow to heart muscle that cannot be managed through conventional drug, catheter or surgical therapy • Causes constant & severe heart pain • Large & growing population of untreatable patients • Improved cardiac care leads to less mortality &

  5. Slide 5: Reducer Market Opportunity

    Reducer Market Opportunity • ~ 2,000,000 existing “no option” refractory angina patients in US & Europe • ~400,000 new “no option” patients diagnosed annually • ~1,000,000 patients/year treated for “recurrent” angina 5

  6. Slide 6: Reducer Method of Action

    Reducer Method of Action Reducer modulates outflow of blood from coronary veins, increasing blood flow to ischemic areas Blood flow takes path of Venous back pressure least resistance causes more uniform • Majority of blood flows distribution of blood around ischemic flow through heart areas muscle

  7. Slide 7: Reducer Procedure

    Reducer Procedure • Based on 1950’s surgical procedure (Beck Procedure) • Reported excellent results but is no longer performed due to surgery’s invasiveness • Neovasc Reducer achieves same narrowing using modern non-surgical catheter-based techniques • Reducer procedure takes ~20 minutes; patient d

  8. Slide 8: Reducer Clinical Results

    Reducer Clinical Results Compelling clinical data from 1st human trial (15 patients, 3 centers) • 6-month data published in May 2007 JACC demonstrated safety & significant improvement of angina symptoms • 3-year follow-up data confirms excellent long-term safety & treatment durability (presented at

  9. Slide 9: Reducer COSIRA Trial

    Reducer COSIRA Trial COSIRA (Coronary Sinus Reducer for Treatment of Refractory Angina) Double-blind, randomized, sham-controlled, multicenter, prospective trial • 124 patients • Randomized 1:1 to blinded treatment & sham control arms • Primary endpoint: Efficacy at 6-months • Sites in Belgium, Cana

  10. Slide 10: Reducer Commercialization Timeline

    Reducer Commercialization Timeline Europe: • CE mark received November 2011 • Complete COSIRA enrollment in 2012 • Collect additional clinical data through patient registries being initiated in Europe & Israel • Launch with distribution partner(s) following completion of COSIRA US: FDA IDE trial to

  11. Slide 11: Biological Tissue Products

    Biological Tissue Products • Proprietary process creates implantable, biocompatible tissue that retains strength & physical characteristics of natural tissue • Developed specifically for fabricating surgical heart valves • 20+ year implant history • FDA-cleared, CE-marked, EDQM certified • State-of-

  12. Slide 12: Biological Tissue Business

    Biological Tissue Business Neovasc provides: • Custom biological tissue to wide range of industry partners for use in their devices such as surgical patches & transcatheter heart valves • Development & prototyping services for devices incorporating pericardial tissue • Pilot & commercial manufacturi

  13. Slide 13: Rapid Growth in Heart Valve Applications

    Rapid Growth in Heart Valve Applications • 2011 worldwide sales of 1st generation transcatheter aortic valves estimated at ~$600M, with 2012 sales forecasted at ~$900M • Significant growth expected to continue as 2nd & 3rd generation products reach commercialization Neovasc is the leading independen

  14. Slide 14: Tiara Mitral Valve Replacement

    Tiara Mitral Valve Replacement • Neovasc is developing Tiara, a novel transcatheter device for the treatment of mitral regurgitation (MR) • MR is a serious & widespread condition that can cause significant disability or death • Tiara is delivered using a catheter inserted through apex of heart to re

  15. Slide 15: Tiara Key Features

    Tiara Key Features • Design is specific to mitral anatomy & matches natural shape of mitral annulus • Resists high dislodgment forces during systole • Exerts minimal radial force on mitral annulus • Does not inhibit LV function or obstruct LVOT • Preserves native structures in LV (chordae, papillary

  16. Slide 16: Tiara Development Progress

    Tiara Development Progress • Multiple patent applications filed • Refined valves & transapical delivery systems developed • Preclinical testing underway (bench, acute / chronic animal) • Durability (accelerated wear) testing underway • Clinical technique developed & refined through multiple animal i

  17. Slide 17: Tiara Market Opportunity

    Tiara Market Opportunity • Success of transcatheter aortic valves has positioned transcatheter mitral valve replacement as major area of industry/clinical interest • 600,000 new patients per year with MR in US & EU • Only 20% of diagnosed patients currently undergo surgery • Minimally invasive mitra

  18. Slide 18: Clinical Opinion Leaders

    Clinical Opinion Leaders Leaders in interventional cardiology are assisting Neovasc programs • Dr. Shmuel Banai (Tel Aviv Medical Center) • Dr. Elazer Edelman (Harvard – MIT, Cambridge) • Dr. Tim Henry (Minneapolis Heart Institute) • Dr. Marc Jolicoeur (Montreal Heart Institute) • Dr. Martin Leon (C

  19. Slide 19: 2012: Looking Forward

    2012: Looking Forward Continued growth of tissue business (2011 ~$5.25M) • Expect steady growth in 2012 with upside potential as customers’ new products are commercialized Complete COSIRA trial for Reducer & launch in Europe • Controlled EU release in near-term to build clinical experience / data th

  20. Slide 20: Capitalization & Trading

    Capitalization & Trading • 45.8m (issued & outstanding) Shares outstanding • 55.6m (fully diluted) Public listing • TSXV: NVC • Frost Group • Gagnon Securities Key investors • Peregrine Ventures • OPKO Health • Company directors & management • August 2011 financing oversubscribed (raised $4.7M) Cash

  21. Slide 21: Thank you

    Thank you 21

Neovasc — Investor Presentation (May 2012) on 6ix